CAMBRIDGE, Mass., May 14, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that data supporting further research and clinical development of MM-398 will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 June 2, 2015 at McCormick Place in Chicago. Presentations include Phase 1 data of an investigator-sponsored study of MM-398 in high-grade glioma, a trials-in-progress abstract describing an investigator-sponsored study of convection-enhanced delivery of concentrated MM-398 in recurrent high-grade glioma, and a trials-in-progress abstract for the MM-302 HERMIONE Phase 2 clinical trial.
Data will be presented in three poster sessions.
Poster Sessions
- HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)
Session Title: Breast CancerHER2/ER (Trials in Progress)
Saturday, May 30, 2015, 8:00 AM - 11:30 AM CT
S Hall A - A phase I study of convection-enhanced delivery of nanoliposomal irinotecan using real-time imaging in patients with recurrent high-grade glioma
Session Title: Central Nervous System Tumors (Trials in Progress)
Monday, June 1, 2015, 1:15 PM - 4:45 PM CT
S Hall A - A phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas
Session Title: Central Nervous System Tumors
Monday, June 1, 2015, 1:15 PM - 4:45 PM CT
S Hall A
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has submitted a New Drug Application for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. For more information, please visit Merrimack's website at www.merrimackpharma.com or connect on Twitter at @MerrimackPharma.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT:
Media Contact:
Debbie Tseng, Merrimack
617-441-7659
dtseng@merrimackpharma.com
Investor Contact:
Geoffrey Grande, CFA
Merrimack
617-441-7602
ggrande@merrimackpharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-pharmaceuticals-announces-presentations-at-the-2015-american-society-of-clinical-oncology-asco-annual-meeting-300082946.html
SOURCE Merrimack Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
